GlassScriptPhysician profile
Amanda M Loucks
NPI 1457640476
$13,101.33
in general payments reported to CMS, 2019-2025
49 companies · $2,101 in 2025
The $2,101 reported for 2025 was more than what 94% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,882 · 2020: $1,186 · 2021: $1,960 · 2022: $1,966 · 2023: $1,916 · 2024: $2,090 · 2025: $2,101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,107.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,011.02 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,840.50 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,316.61 | 2019-2025 | |
| Lilly USA, LLC | $1,078.37 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,005.52 | 2019-2025 | Jardiance |
| Amgen INC. | $959.64 | 2019-2025 | Repatha, Otezla, Otezla |
| Abbvie INC. | $912.17 | 2021-2025 | |
| Amarin Pharma, INC. | $526.81 | 2019-2022 | |
| Abbott Laboratories | $336.06 | 2021-2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $290.13 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $282.06 | 2019-2025 | Capvaxive, Gardasil 9, Vaxelis |
| E.R. Squibb & Sons, L.L.C. | $265.24 | 2019-2025 | Eliquis, Camzyos |
| Janssen Pharmaceuticals, INC | $247.41 | 2019-2024 | Xarelto |
| Takeda Pharmaceuticals U.S.A., INC. | $209.03 | 2019-2021 | |
| Esperion Therapeutics, INC. | $190.66 | 2020-2024 | Nexletol |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Loucks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.